Clusterin inhibition using OGX-011 synergistically enhances antitumour activity of sorafenib in a human renal cell carcinoma model

BACKGROUND: The objective of this study was to investigate whether the therapeutic activity of sorafenib could be enhanced by combining with OGX-011, an antisense oligodeoxynucleotide (ODN) targeting clusterin, in renal cell carcinoma (RCC). METHODS: We investigated the effects of combined treatment...

Descripción completa

Detalles Bibliográficos
Autores principales: Kususda, Y, Miyake, H, Gleave, M E, Fujisawa, M
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2012
Materias:
Translational Therapeutics
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3388571/
https://www.ncbi.nlm.nih.gov/pubmed/22588555
http://dx.doi.org/10.1038/bjc.2012.209

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3388571/
https://www.ncbi.nlm.nih.gov/pubmed/22588555
http://dx.doi.org/10.1038/bjc.2012.209

Ejemplares similares